Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pseudovav - A Cancer Vaccine Targeting Mutated GNAS Combined With Immune Checkpoint Inhibition for Patienes With Pseudomyxoma Peritonei

NCT07341360 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT07341360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07341360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pseudovav - A Cancer Vaccine Targeting Mutated GNAS Combined With Immune Checkpoint Inhibition for Patienes With Pseudomyxoma Peritonei
Lead sponsor
Oslo University Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
October 13, 2025
Completion date
December 31, 2034
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pseudomyxoma peritonei